Inwardly rectifying potassium channel (Kir channel) (Kir channel)

Inwardly rectifying potassium (Kir) channels are a diverse family of ion channels that preferentially allow the flow of potassium ions into the cell rather than out of it. Structurally, they are composed of four subunits, each containing two transmembrane helices, which distinguish them from the six-transmembrane voltage-gated potassium channels. This unique "inward rectification" property is not intrinsic to the protein itself but results from the voltage-dependent blockade of the channel pore by intracellular polyamines and magnesium ions during depolarization. These channels play a fundamental role in stabilizing the resting membrane potential and regulating the excitability of neurons, cardiomyocytes, and endocrine cells. For instance, the Kir6.x subfamily (K-ATP channels) couples cellular metabolism to membrane potential, thereby controlling insulin release in the pancreas. Mutations in Kir channel genes are linked to various channelopathies, including neonatal diabetes, Andersen-Tawil syndrome, and Bartter syndrome. Consequently, they are significant therapeutic targets for drugs ranging from sulfonylureas used in type 2 diabetes to anti-arrhythmic agents and potential novel diuretics.

Other names

KirIRKInward rectifier potassium channelKCNJ family2-transmembrane domain potassium channel

Drugs targeting Kir channels typically act as either pore blockers (inhibitors) or channel openers (activators). For example, sulfonylureas inhibit K-ATP channels to stimulate insulin secretion, while diazoxide opens them to inhibit secretion. Other agents may interfere with the binding of regulatory molecules like PIP2 or intracellular polyamines to modulate channel conductance.